Insulet’s Strong Market Position and Growth Potential Justifies Buy Rating
Analyst Jeff Johnson from Robert W. Baird maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...
medtechdive2d
Tandem, Insulet tout Type 2 expectations as tech attracts new users
Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...
drugdeliverybusiness4d
Insulin pump maker PharmaSens adds former ADA leaders, medtech veterans to board
PharmaSens announced today that it appointed Dr. Robert A. Gabbay and James L. Peterson to its board of directors.
Insulet raises annual revenue forecast on strong demand for insulin pumps
Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps. Shares of the medical device maker rose about 2.5% to $251 in extended trading.
Yahoo Finance18d
Luna Diabetes trials automated wearable insulin pump
The Luna system was developed as a wearable insulin pump and alternative to insulin pen to automate the insulin delivery ...
Yahoo Finance1h
Modular Medical Proudly Sponsors the Inaugural Achieving Diabetes Equity in Practice Today (ADEPT) Conference
SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump ...
HME News4d
PharmaSens adds two to board
PharmaSens, a developer of insulin patch pumps for people with diabetes, has appointed Robert A. Gabbay, MD, PhD, FACP and James L. Peterson to its board of directors.